3-methoxycarbonyl-1-methyl-pyridinium | 18899-18-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-methoxycarbonyl-1-methyl-pyridinium
• 英文别名: 1-Methyl-3-methoxycarbonyl-pyridinium；1-Methyl-3-methoxycarbonylpyridinium；3-Methoxycarbonyl-1-methylpyridinium；3-(Methoxycarbonyl)-1-methylpyridinium；methyl 1-methylpyridin-1-ium-3-carboxylate
• CAS: 18899-18-8
• 化学式: C₈H₁₀NO₂
• 分子量: 152.173
• InChiKey: PUCDEIAKSXKMSO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-methoxycarbonyl-1-methyl-pyridinium 、 2-氯丙烯腈 在 copper(l) iodide 、 水 、 锌 作用下， 以 乙醇 为溶剂， 反应 20.0h， 以62%的产率得到methyl 4-(2-cyanoethyl)-1-methyl-4H-pyridine-3-carboxylate
  参考文献：
  名称：

  NAD型自由基的有效捕获。吡啶鎓盐的非仿生还原。

  摘要：

  吡啶鎓盐（NAD +类似物）的单电子还原生成二氢吡啶基，然后可将其用于自由基加成过程中，以区域选择性地形成γ-取代的二氢吡啶。

  DOI：

  10.1039/b201813f
• 作为产物：
  描述：

  烟酸 、 碘甲烷 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 乙腈 为溶剂， 反应 4.17h， 以72%的产率得到烟酸甲酯
  参考文献：
  名称：

  DBU-CH3I，一种潜在的 CH2N2 替代品，用于制备甲基酯和甲基芳基醚：用各种酸进行研究

  摘要：

  摘要 DBU-CH3I 已准备好在由羧酸制备甲酯中替代重氮甲烷。反应可以在商业未处理的丙酮和乙腈中进行，已经以几种甲酯为例，否则很难制备。使用二碘甲烷的双酯化也可以类似方式实现。足够酸性的酚也可以方便地通过该方法O-甲基化。

  DOI：

  10.1080/00397910802238809

文献信息

• Novel Drugs for Dementia
  申请人：Ternansky Robert

  公开号：US20080227806A1

  公开（公告）日：2008-09-18

  The invention is directed to compounds that are prodrugs containing a chemical delivery system (CDS) moiety and a cysteine protease inhibitor moiety. The CDS moiety targets the prodrug to the brain or central nervous system. The cysteine protease inhibitor inhibits cysteine proteases upon release from the prodrug. Cysteine protease inhibitors are effective for treating dementia, Alzheimer's disease and vascular dementia. Targeting the brain or central nervous system offers significant advantages in treating these conditions and diseases. A preferred CDS prodrug is a dihydrotrigoneline CDS moiety coupled to an epoxysuccinyl peptide cysteine protease inhibitor moiety.

  本发明涉及一种含有化学递送系统（CDS）基团和半胱氨酸蛋白酶抑制剂基团的前药化合物。CDS基团将前药定位于大脑或中枢神经系统。半胱氨酸蛋白酶抑制剂在从前药中释放后抑制半胱氨酸蛋白酶。半胱氨酸蛋白酶抑制剂对治疗痴呆症、阿尔茨海默病和血管性痴呆症有效。定位于大脑或中枢神经系统在治疗这些疾病和症状方面具有显著的优势。首选的CDS前药是将二氢三角线CDS基团与环氧丙酰肽半胱氨酸蛋白酶抑制剂基团耦合。
• Chemosensory receptor ligand-based therapies
  申请人：Anji Pharma (US) LLC

  公开号：US10610500B2

  公开（公告）日：2020-04-07

  Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.

  本文提供了通过施用包含化感受体配体（如苦味受体配体）的组合物来治疗与化感受体相关的病症（包括糖尿病、肥胖症和其他代谢性疾病、失调或病症）的方法。本文还提供了化学感觉受体配体组合物，包括苦味受体配体组合物，及其用于本发明方法的制备方法。本文还提供了包含二甲双胍及其盐类的组合物和使用方法。
• DERIVES DE 1H-INDOLE-PYRIDINECARBOXAMIDE ET DE 1H-INDOLE-PIPERIDINECARBOXAMIDE ET LEUR UTILISATION COMME INDUCTEURS DE TYROSINE HYDROXYLASE
  申请人：Les Laboratoires Servier

  公开号：EP1931341B1

  公开（公告）日：2009-11-04
• SYNTHESIS AND USES OF PYROGLUTAMIC ACID DERIVATIVES
  申请人：Alvarez Builla Gomez Julio

  公开号：US20070249678A1

  公开（公告）日：2007-10-25

  Novel pyroglutamic acid derivatives (I), wherein R 1 is −OH, −ORa, wherein Ra is alkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, aralkyl or heterocyclyl; R 2 , R 3 and R 4 are independently H, a nitrogen protecting group which hydrolyzes under acidic conditions or phtalamide; X is a pharmaceutically acceptable anion; and Y is a N-containing group; either in the form of their isolated optically active stereoisomers or in the form of mixtures thereof, are useful compounds for enhancing an immuneresponse in a subject and/or for treating tumours, bacterial, fungal or viral infections, or autoimmune diseases.
• Chemosensory Receptor Ligand-Based Therapies
  申请人：BARON Alain D.

  公开号：US20120177730A1

  公开（公告）日：2012-07-12

  Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.